Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
13.62
-0.11 (-0.80%)
At close: Aug 31, 2026, 4:00 PM EDT
13.39
-0.23 (-1.69%)
Pre-market: Sep 1, 2026, 9:09 AM EDT
Summit Therapeutics Employees
Summit Therapeutics had 265 employees as of December 31, 2025. The number of employees increased by 106 or 66.67% compared to the previous year.
Employees
265
Change (1Y)
106
Growth (1Y)
66.67%
Revenue / Employee
n/a
Profits / Employee
-$3,230,525
Market Cap
10.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 265 | 106 | 66.67% |
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,000 |
| Ionis Pharmaceuticals | 1,480 |
| Axsome Therapeutics | 1,346 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
SMMT News
- 6 days ago - Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study - TheFly
- 6 days ago - Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China - Business Wire
- 7 days ago - Summit announces publication of primary analysis results from Phase III HARMONi - TheFly
- 7 days ago - Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology - Business Wire
- 7 days ago - Summit Therapeutics upgraded to Market Perform from Underperform at Bernstein - TheFly
- 14 days ago - Summit Therapeutics falls -8.5% - TheFly
- 15 days ago - Summit Therapeutics upgraded to Market Perform from Underperform at Leerink - TheFly
- 15 days ago - Summit says Akeso receives marketing authorization in China for ivonescimab - TheFly